March 29, 2021
Phase I/II studies to evaluate human placental hematopoietic stem cell–derived natural killer (NK) cell therapy to treat COVID-19 in hospitalized adults are currently ongoing as part of our partnership with the Infectious Disease Research Institute (IDRI).
news & events
Check out what we’ve been up to and where can we connect!
March 29, 2021
February 8, 2021
In a recent podcast discussion with TrialSite News, Claudia Christian, Senior Vice President, Clinical Operations at FHI Clinical, shares how the company’s experience in complex clinical research in resource-limited settings helps to ensure health equity and get life-saving vaccines to those who need them most.
ACTT-2 findings support FDA emergency use authorization for baricitinib + remdesivir to treat COVID-19
November 20, 2020
The U.S. FDA granted emergency use authorization (EUA) for the use of baricitinib in combination with remdesivir to treat COVID-19 in hospitalized adults and children at least two years of age requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation.
October 20, 2020
Rob King of FHI Clinical recently spoke with the editor for Outsourcing-Pharma about the Oracle Health Sciences and FHI Clinical collaboration to improve clinical trial efficiency and help get therapies to market faster.
April 29, 2021
Biomedical researchers, clinical research organizations, people infected and impacted by the pandemic, along with Black barbers and stylists, will come together in a virtual event April 29 at 6 p.m. to provide straight talk about fears, trust issues, and why we need our Black and Brown community to be part of COVID-19 vaccine research.
April 21, 2021
Join us for this panel discussion in which experts in infectious diseases will discuss the effect of WHO recommendations around TPT for individuals at high risk of TB infection and increased TPT use on TB vaccine development.